Isoniazid induced hepatic failure. A case report;Insuficiencia hepatica pelo uso de isoniazida. Relato de caso+

Arquivos de Gastroenterologia

Volumn 37, Issue 1, 2000, Pages 72-75

  Pereira, Ricardo Mendes ^a,b   Tresoldi, Antonia Teresinha ^a   Hessel, Gabriel ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Cidade Universitaria   (Brazil)

Author keywords

Child; Hepatitis; Isoniazid, adverse effects; Liver failure; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; CASE REPORT; DRUG METABOLISM; DRUG SAFETY; HUMAN; INFANT; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; LUNG TUBERCULOSIS; MALE; TOXIC HEPATITIS; TUBERCULOUS MENINGITIS; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION;

ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS, TOXIC; HUMANS; INFANT; ISONIAZID; LIVER FAILURE, ACUTE; MALE; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, MENINGEAL; TUBERCULOSIS, PULMONARY;

EID: 0033940884     PISSN: 00042803     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-28032000000100014     Document Type: Article

References (13)

1. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, Bismuth H, Belghiti J, Erlinger S, Rueff B, Benhamou JP. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995;21:929.
2. Durand F, Jebrak G, Pessayre D, Fournier M. Hepatotoxicity of antitubercular treatments. Drug Saf 1996;15:394.
3. Franks AL, Binkin NJ, Saider DE. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989;104:151.
4. Furet Y, Metman EH, Bertrand J. Hepatite mixte a la rifampycine [Letter]. Therapie 1986;41:405.
5. McDermont J, Ormond L, Muschenheim C. Pyrazinamide and isoniazid in tuberculosis. Am Rev Tuberc 1954;69:319.
6. Nolan CM, Sandblom RE, Thummel KE. Hepatotoxicity associated with acetominophem usage in-patients receiving multiple drug therapy for tuberculosis. Chest 1994;105:408.
7. Ormerod LP, Kkinner C, Wales J. Hepatotoxicity of antituberculous drugs. Thorax 1996;51:111.
8. Ozick LA, Lee TP, Jacob L. Early hepatotoxity from antituberculous treatment in alcoholics and AIDS patients. Hepatology 1991;14:275.
9. Pessayre D, Bentata M, Degott C, Nouel O, Miguet JP, Rueff B, Benhamou JP. Isoniazid-rifampicin induced fulminant hepatitis: a possible consequence of hepatotoxicity by enzyme induction. Gastroenterology 1977;72:284.
10. Sherlock S. Fígado e drogas. In: Sherlock S. Doenças do fígado e do sistema biliar. 7. ed. Rio de Janeiro; Guanabara Koogan; 1988. p. 280-308.
11. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month regimens of chemotherapy given intermittently in the continuation phase of treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985;132:374.
12. Snider DE, Caras GJ. Isoniazid associated hepatitis death - a review of available information. Am Rev Respir Dis 1992;145:494.
13. Wu JC, Lee SD, Yeh PF. Isoniazid rifampicin induced hepatitis in hepatitis B carriers. Gastroenterology 1990;98:502.